Design, synthesis and evaluation of antitumor acylated monoaminopyrroloquinazolines

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Pyrroloquinazoline is a privileged chemical scaffold with diverse biological activities. We recently described a series of N-3 acylated 1,3-diaminopyrroloquinazolines with potent anticancer activities. The N-1 primary amino group in 1,3-diaminopyrroloquinazoline is critical for its inhibitory activity against dihydrofolate reductase (DHFR). In order to design out this unnecessary DHFR inhibition activity and further expand the chemical space associated with pyrroloquinazoline, we removed the N-1 primary amino group. In this report, we describe our design and synthesis of a series of N-3 acylated monoaminopyrroloquinazolines. Biological evaluation of these compounds identified a naphthamide 4a as a potent anticancer agent (GI50 = 88–200 nM), suggesting that removing the N-1 primary amino group in 1,3-diaminopyrroloquinazoline is a useful chemical modification that can be introduced to improve the anticancer activity.

Original languageEnglish (US)
Pages (from-to)3107-3110
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume27
Issue number14
DOIs
StatePublished - 2017

Keywords

  • Anticancer
  • Privileged scaffold
  • Pyrroloquinazoline
  • Reduction

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Design, synthesis and evaluation of antitumor acylated monoaminopyrroloquinazolines'. Together they form a unique fingerprint.

Cite this